Supreme Court Temporarily Halts Ban on Mifepristone Mail Prescriptions
The United States Supreme Court has issued a temporary stay on a federal appeals court ruling that prohibited the mail distribution of mifepristone, a medication commonly used for abortion. This decision allows telemedicine prescriptions and mail dispensing of mifepristone to continue while the Court considers further action.
Background of the Case
In 2023, the Food and Drug Administration (FDA) implemented a rule permitting mifepristone to be prescribed via telemedicine and dispensed through mail services. This policy aimed to enhance access to abortion services, especially during the COVID-19 pandemic. However, the state of Louisiana challenged this rule, arguing that the FDA's decision was based on flawed data and lacked adequate consideration.
Appeals Court Ruling
On May 1, 2026, a unanimous three-judge panel of the Fifth Circuit Court of Appeals sided with Louisiana, finding that the state was likely to succeed on the merits of its case. The court stayed the FDA rule nationwide, effectively reinstating the requirement for in-person prescriptions and dispensing of mifepristone.
Supreme Court's Intervention
In response to emergency applications from mifepristone manufacturers Danco Laboratories and GenBioPro, Supreme Court Justice Samuel Alito issued an administrative stay on May 4, 2026. This stay temporarily halts the Fifth Circuit's ruling, allowing the continued use of telemedicine and mail services for mifepristone prescriptions until at least May 11, 2026. The Court has requested responses from Louisiana and other respondents by May 7, 2026.
Implications and Next Steps
This temporary stay maintains the status quo, ensuring that mifepristone remains accessible via telemedicine and mail while the Supreme Court deliberates on the case. The Court's decision to intervene highlights the ongoing legal complexities surrounding abortion access in the United States. Stakeholders on both sides await further developments as the Court considers whether to extend the stay or allow the Fifth Circuit's ruling to take effect.
For more detailed information, refer to the original article on JURIST: Supreme Court Temporarily Halts Federal Appeals Court Ban on Mifepristone Mail Prescriptions.
